Assessments of hepatitis B virus-like particles and Crm197 as carrier proteins in melioidosis glycoconjugate vaccines
M. Bayliss, G. Pergolizzi, M. I. Donaldson, A. E. Scott, S. A. Nepogodiev, L. Beales, M. Whelan, W. Rosenberg, H. Peyret, G. P. Lomonossoff, N. J. Harmer, T. Atkins, R. A. Field, J. L. Prior
This study compares the effectiveness of Crm197 and hepatitis B virus-like particles as carrier proteins for a melioidosis glycoconjugate vaccine, finding that Crm197 conjugates produce higher antibody titres but both protect against bacterial challenge.
bioRxiv · Apr 8, 2020 · PreprintImmunology